Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V501 in 16- to 26-year-old Japanese Men
NCT01862874Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2013
- Primary completion
- Aug 2017
- Modality
- Vaccines & Immunotherapeutics
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, condyloma acuminata, sponsored by Merck & Co.. Started Jun 2013; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectioncondyloma acuminata
Beyond the preview
Go deeper on NCT01862874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01862874.